Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investors Presentation of the Company. The presentation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care Ltd submitted its investors presentation to BSE, highlighting key operational updates. The company received USFDA approval in June 2025 for Drug (OTC) exports and has already executed 3 export shipments to the US, targeting 4-5 shipments monthly. Specific orders disclosed include a ₹0.74 crore oral care export order and a ₹0.48 crore skincare/facecare manufacturing order. Management guided FY26 revenue at ₹35-40 crore with 10% PAT. A ₹33 crore expansion is planned via rights issue at ₹25 per share, and the company has onboarded a 125-year-old FMCG group in the personal/household care segment. New Veer Plast division launched for backward integration in packaging.
Positive signal for shareholders — USFDA approval unlocks export markets, specific order pipeline reduces execution risk, and management's revenue/PAT guidance suggests strong growth visibility. The ₹33 crore rights issue may cause near-term dilution but funds a clearly-articulated expansion plan.